scholarly journals Clinical Evaluation of Transarterial Infusion Chemotherapy for Advanced Esophageal Cancer

2021 ◽  
Vol 12 (5) ◽  
pp. 1493-1498
Author(s):  
Mei-Pan Yin ◽  
Peng-Fei Xie ◽  
Yue Zhao ◽  
Wei He ◽  
Yao-Zhen Ma ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Clinical Evaluation ◽  
Advanced Esophageal Cancer ◽  
Infusion Chemotherapy ◽  
Transarterial Infusion

scholarly journals Clinical evaluation of transarterial infusion chemotherapy for advanced esophageal cancer

2019 ◽  
Author(s):  
Yan-Wei Zeng ◽  
Mei-Pan Yin ◽  
Yue Zhao ◽  
Wei He ◽  
Yao-Zhen Ma ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Esophageal Carcinoma ◽  
Complete Response ◽  
Clinical Results ◽  
Local Chemotherapy ◽  
Infusion Chemotherapy ◽  
Total Treatment ◽  
Radical Radiation ◽  
Transarterial Infusion

Abstract Background:Most esophageal cancer patients were diagnosed at an advanced stage where there are few effective treatment. Transarterial infusion chemotherapy(TAI) is a local chemotherapy method wherein chemotherapeutic drugs are directly injected into tumor vessels. Methods: TAI was performed on advanced esophageal carcinoma patients once a month, and each patient underwent 1–3 treatments. The clinical results, complications, and effectiveness rates of each treatment episode were recorded and analyzed. Results: TAI was successfully performed in all patients, and no severe complications such as paraplegia or death were noted. Complete response (CR), partial response (PR), and stable disease (SD) were noted in 17.3% (13/75), 77.3% (58/75), and 5.3% (4/75) of cases after TAI, respectively. The total treatment efficacy (CR+PR) was 94.7%. All cases exhibited improvement in clinical stages, with a marked decrease in dysphagia. Subsequent treatments were administered to 13 patients, including radical radiation in 7 and chemotherapy in 6. During follow-up, death was caused by progressive carcinoma in 20, tumor-related pneumatic infection and respiratory failure in 11, and gastrointestinal hemorrhage in 17. The median survival time was 15 months and the 1-year survival rate was 58.1%. Conclusions: TAI chemotherapy may be safely used for advanced esophageal carcinoma treatment.

Clinical evaluation of adjuvant chemoradiotherapy with CDDP, 5-Fu, and VP-16 for advanced esophageal cancer

1998 ◽  
Vol 46 (1) ◽  
pp. 11-17 ◽  
Author(s):  
Hidenori Mukaida ◽  
Toshihiro Hirai ◽  
Yoshinori Yamashita ◽  
Kazuhiro Yoshida ◽  
Jun Hihara ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Clinical Evaluation ◽  
Adjuvant Chemoradiotherapy ◽  
Advanced Esophageal Cancer

scholarly journals Sequential Treatment of Severe Airway Stenosis Caused by Esophageal Cancer by Using Airway Stent Implantation and Arterial Infusion Chemotherapy

2021 ◽  
Author(s):  
Pengfei Xie ◽  
Shuai Wang ◽  
Wei He ◽  
Meipan Yin ◽  
Chunxia Li ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Stent Implantation ◽  
Arterial Infusion ◽  
Arterial Infusion Chemotherapy ◽  
Airway Stenosis ◽  
Infusion Chemotherapy ◽  
Airway Stent ◽  
Airway Stenting ◽  
Transarterial Infusion ◽  
Grade Iii

Abstract Purpose: This study was aimed at investigating the safety and efficacy of airway stent implantation and transarterial infusion chemotherapy for the treatment of severe airway stenosis caused by esophageal cancer. Methods: Data of patients with advanced esophageal cancer complicated by severe airway stenosis treated with airway stent implantation and transarterial infusion chemotherapy were retrospectively analyzed. Furthermore, dyspnea, clinical efficacy, adverse reactions, and survival were evaluated. Results: Of the 71 patients included, 28, 43, 34, 35, and 2 patients had grade III dyspnea, grade IV dyspnea before airway stenting, grade I dyspnea, grade III dyspnea, and grade III dyspnea after airway stenting, respectively. After airway stent implantation and 1–3 courses of transarterial infusion chemotherapy, complete response, partial response, and stable disease were noted in 11, 41, and 19 patients, respectively. Total objective response rate (ORR) and disease control rate (DCR) were 73.2% and 100.0%, respectively. During follow-up, 32, 24, and 10 patients died of organ failure, tumor-related respiratory failure, and gastrointestinal bleeding, respectively. The median survival time was 8 months, and the 1-year survival rate was 40.8%.Conclusions: Airway stent implantation combined with arterial infusion chemotherapy is safe and effective in the sequential treatment of esophageal cancer with severe airway stenosis.

Helical tomotherapy for advanced esophageal cancer improves target conformity and homogeneity: A comparison with fixed-field intensity-modulated radiotherapy

2015 ◽  
Vol 11 (3) ◽  
pp. 3146-3155
Author(s):  
Luhua Wang
Keyword(s):  
Esophageal Cancer ◽  
Field Intensity ◽  
Helical Tomotherapy ◽  
Intensity Modulated Radiotherapy ◽  
Matched Pair ◽  
Conformity Index ◽  
Target Coverage ◽  
Advanced Esophageal Cancer ◽  
Fixed Field ◽  
Intensity Modulated

Purpose: To evaluate the usefulness of helical tomotherapy (HT) in the treatment of advanced esophageal cancer (EC) and compare target homogeneity, conformity and normal tissue doses between HT and fixed-field intensity-modulated radiotherapy (ff-IMRT).Methods: In all, 23 patients with cT3-4N0-1M0-1a thoracic EC (upper esophagus, 9 patients; middle esophagus, 6; distal esophagus, 6 and esophagogastric junction, 2) who were treated with ff-IMRT (60 Gy in 30 fractions) were re-planned for HT and ff-IMRT with the same clinical require­ments. Comparisons were performed using the Wilcoxon matched-pair signed-rank test.Results: Compared with ff-IMRT, HT significantly reduced the homogeneity index for thoracic, upper, middle and distal ECs by 38%, 31%, 36% and 33%, respectively (P < 0.05). The conformity index was increased by HT for thoracic, upper and middle ECs by 9%, 9% and 18%, respectively (P < 0.05). Target coverage was improved by 1% with HT (P < 0.05). The mean lung dose was significantly reduced by HT for thoracic and upper ECs (P < 0.05). The V20 (volume receiving at least 20 Gy) and higher dose volumes of the lungs were decreased by HT in all cases, but the differences were significant for thoracic, upper and distal ECs (P < 0.05), with reductions of 2.1%, 3.1% and 2.2%, respectively. HT resulted in a larger lung V5 for thoracic, upper, middle and distal ECs, with increases of 3.5%, 1.5%, 7.2% and 3.2%, respectively. Heart sparing was significantly better with HT than with ff-IMRT in terms of the V30 and V40 for thoracic, upper, middle and distal ECs (P < 0.05).Conclusions: Compared to ff-IMRT, HT provides superior target coverage, conformity and homogeneity, with reduced the volume of high doses to the lungs and heart for advanced EC. HT may be a treatment option for advanced EC, especially upper EC.

Sign in / Sign up

Export Citation Format

Share Document